New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Moderna, Inc. (MRNA) Revenue growth

Alert me on Revenue growth

Moderna, Inc.'s revenue growth over the twelve months to Sep 30, 2026 was 13.1%, up 53.1 percentage points from fiscal 2025 (−39.9%). Over the past ten years it has ranged from −64.5% (fiscal 2023) to 2,200.3% (fiscal 2021); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of 7.20% and above the Healthcare sector median of 8.62%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 −39.9% 12.82
FY2024 −52.8% 11.70
FY2023 −64.5% (68.74)
FY2022 4.29% (2,195.96)
FY2021 2,200.3% 961.92
FY2020 1,238.3% 1,293.91
FY2019 −55.6% (21.20)
FY2018 −34.4% (124.26)
FY2017 89.9% 137.26
FY2016 −47.4% —

Quarterly newest first

Period Revenue growth Change (points)
Sep 2026 29.2% 27.12
Jun 2026 2.11% (258.08)
Mar 2026 260.2% 290.00
Dec 2025 −29.8% 15.63
31 more quarters

Against its own ten years

Low −64.5% High 2,200.3%
Ten-year median −37.2%
Current reading's percentile 50

Revenue growth against peers

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on MRNA